Tenderwize
Retour à la recherche

Discount Agreement for Doravirin/Lamivudin/Tenofovir

Techniker Krankenkasse·Hamburg, Germany·Deadline Nov 29, 2027 · 460 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-32 - Doravirin/Lamivudin/Tenofovir (Wirkstoffkombination)

30/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

30 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or volume guarantees; uncertain revenue potential.

Contract terminates automatically on patent/market exclusivity expiry, possibly before end of term.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Supply of pharmaceutical product Doravirin/Lamivudin/Tenofovir
  • Enter into a discount agreement (Rabattvertrag) with TK
Afficher le résumé complet

This is an Open House procedure by Techniker Krankenkasse (TK) for concluding discount agreements (Rabattverträge) for the drug combination Doravirin/Lamivudin/Tenofovir. No estimated value is provided. The procedure is open to all eligible pharmaceutical manufacturers meeting specific criteria. Contracts are non-exclusive, with a maximum term of 24 months ending 30 November 2027. Joining is possible at any time during the term. No award criteria apply; any qualifying supplier will be accepted.

Risques

No estimated value or volume guarantees; uncertain revenue potential.

Contract terminates automatically on patent/market exclusivity expiry, possibly before end of term.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical manufacturer (pharmazeutischer Unternehmer) as per §4(18) AMG
  • Must have a valid marketing authorization for the drug combination or be authorized to market it
  • Must have seat in Germany, another EU member state, or EEA

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Discount Agreement for Doravirin/Lamivudin/Tenofovir

Conclusion of discount contracts for the drug combination Doravirin/Lamivudin/Tenofovir under §130c SGB V. Non-exclusive, standardized terms, no negotiations.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Nov 2025 - Nov 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 29, 2027

Détails de la procédure

Date de publication
12 Oct 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
670890-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3